Éric Lefebvre

9.5k citations

137 papers · 6.2k indexed · 3 hit papers · h-index 39

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 34
- HIV Research and Treatment 34
Hepatology 23
- Hepatitis C virus research 11

Co-authors: Tony Vangeneugden (19 shared papers)V. Malka (8 shared papers)Martine De Pauw (13 shared papers)Sabrina Spinosa‐Guzman (7 shared papers)Richard M. W. Hoetelmans (14 shared papers)Vanitha Sekar (12 shared papers)Sandra De Meyer (5 shared papers)F. Burgy (1 shared paper)
Journals: Journal of Hepatology (9 papers)AIDS (7 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (5 papers)Physical Review Letters (5 papers)Physics of Plasmas (4 papers)
Partner nations: France United States Canada

In The Last Decade

Éric Lefebvre

130 papers receiving 5.9k citations

Hit Papers

align trajectories log scale

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis 2017 · 421 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Hepatology
2011 Nature Physics
2004 Physical Review Letters

Peers

Countries citing papers authored by Éric Lefebvre

Since Specialization

Citations

This map shows the geographic impact of Éric Lefebvre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Lefebvre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Lefebvre more than expected).

Fields of papers citing papers by Éric Lefebvre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Lefebvre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Lefebvre. The network helps show where Éric Lefebvre may publish in the future.

Co-authors

The 25 scholars most cited alongside Éric Lefebvre, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Éric Lefebvre Line = papers co-authored together Éric Lefebvre links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 137 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Production of a keV X-Ray Beam from Synchrotron Radiation in Relativistic Laser-Plasma Interaction Physical Review Letters ·A. Rousse, K. Ta Phuoc, Rahul Shah, A. Pukhov, Éric Lefebvre, V. Malka, S. I. Kiselev, F. Burgy, D. Umstadter, Daniéle Hulin Hit paper breakdown →	2004	467
2	Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis Hepatology ·Oliver Krenkel, Tobias Puengel, Olivier Govaere, Ali T. Abdallah, Jana C. Mossanen, Marlene Kohlhepp, Anke Liepelt, Éric Lefebvre, Tom Luedde, Claus Hellerbrand, Ralf Weiskirchen, Thomas Longerich, Ivan G. Costa, Quentin M. Anstee, Christian Trautwein, Frank Tacke Hit paper breakdown →	2017	421
3	Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials The Lancet ·Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina, David A. Cooper, Jean‐Christophe Goffard, Adriano Lazzarin, A. Wöhrmann, Christine Katlama, Timothy Wilkin, Richard Haubrich, Calvin Cohen, Charles Farthing, Dushyantha Jayaweera, Martin Markowitz, Peter Ruane, Sabrina Spinosa‐Guzman, Éric Lefebvre	2007	367
4	Few femtosecond, few kiloampere electron bunch produced by a laser–plasma accelerator Nature Physics ·O. Lundh, Joonwon Lim, C. Rechatin, L. Ammoura, A. Ben‐Ismaïl, X. Davoine, Guilhem Gallot, J.-P. Goddet, Éric Lefebvre, V. Malka, J. Fauré Hit paper breakdown →	2011	293
5	Damage Control Resuscitation Is Associated With a Reduction in Resuscitation Volumes and Improvement in Survival in 390 Damage Control Laparotomy Patients Annals of Surgery ·Bryan A. Cotton, Neeti Reddy, Quinton Hatch, Éric Lefebvre, Charles E. Wade, Rosemary A. Kozar, Brijesh S. Gill, Rondel Albarado, Michelle K. McNutt, John B. Holcomb	2011	279
6	Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 AIDS ·Roberto Ortiz, Edwin DeJesus, Homayoon Khanlou, Evgeniy Voronin, Jan van Lunzen, Jaime Andrade‐Villanueva, Jan Fourie, Sandra De Meyer, Martine De Pauw, Éric Lefebvre, Tony Vangeneugden, Sabrina Spinosa‐Guzman	2008	278
7	Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial The Lancet ·José Valdez Madruga, Daniel Berger, Marilyn McMurchie, Fredy Suter, Dénes Bánhegyi, Kiat Ruxrungtham, Dorece Norris, Éric Lefebvre, Marie-Pierre de Béthune, Frank Tomaka, Martine De Pauw, Tony Vangeneugden, Sabrina Spinosa‐Guzman	2007	262
8	Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis PLoS ONE ·Éric Lefebvre, Graeme Moyle, Ran Reshef, Lee P. Richman, Melanie Thompson, Hong Feng, Hsin-l Chou, Taishi Hashiguchi, Craig F. Plato, Dominic Poulin, Toni L. Richards, Hiroyuki Yoneyama, Helen Jenkins, Grushenka H.I. Wolfgang, Scott L. Friedman	2016	256
9	Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use AIDS ·Horacio Salomón, Mark A. Wainberg, Bluma Brenner, Yudong Quan, Danielle Rouleau, Pierre Côté, Roger LeBlanc, Éric Lefebvre, Bonnie Spira, C Tsoukas, R P Sékaly, Brian Conway, Douglas L. Mayers, Jean‐Pierre Routy	2000	180
10	Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol‐Induced Liver Damage, Steatosis, and Inflammation in Mice Hepatology ·Aditya Ambade, Patrick Lowe, Karen Kodys, Donna Catalano, Benedek Gyöngyösi, Yeonhee Cho, Arvin Iracheta‐Vellve, Adeyinka Adejumo, Banishree Saha, Charles D. Calenda, Jeeval Mehta, Éric Lefebvre, Pamela Vig, Gyöngyi Szabó	2018	166
11	Proton Acceleration with High-Intensity Ultrahigh-Contrast Laser Pulses Physical Review Letters ·T. Ceccotti, A. Lévy, Horia Popescu, F. Réau, P. D’Oliveira, P. Monot, J. P. Geindre, Éric Lefebvre, Ph. Martin	2007	164
12	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design Contemporary Clinical Trials ·Scott L. Friedman, Arun J. Sanyal, Zachary Goodman, Éric Lefebvre, Mildred D. Gottwald, Laurent Fischer, Vlad Ratziu	2016	161
13	Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients JAIDS Journal of Acquired Immune Deficiency Syndromes ·Calvin Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret Johnson, Michael S. Saag, Khuanchai Supparatpinyo, Herta Crauwels, Éric Lefebvre, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven	2012	130
14	Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials AIDS Research and Human Retroviruses ·Sandra De Meyer, Tony Vangeneugden, Ben Van Baelen, Els De Paepe, Herwig Van Marck, Gastón Picchio, Éric Lefebvre, Marie‐Pierre de Béthune	2008	121
15	Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial HIV Medicine ·Chloe Orkin, E DeJesus, Homayoon Khanlou, Albrecht Stoehr, K Supparatpinyo, Erkki Lathouwers, Éric Lefebvre, Magda Opsomer, Tom Van de Casteele, FL Tomaka	2012	119
16	Business process modeling languages ACM Computing Surveys ·Hafedh Mili, Guy Tremblay, Guitta Bou Jaoude, Éric Lefebvre, Lamia Elabed, Ghizlane El Boussaidi	2010	100
17	Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients AIDS ·Richard Haubrich, Dan Berger, Philippe Chiliade, Amy E. Colson, Marcus A. Conant, Joel E. Gallant, Timothy Wilkin, Jeffrey P. Nadler, Gerald Pierone, Michael S. Saag, Ben Van Baelen, Éric Lefebvre	2007	96
18	Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jean‐Michel Molina, Calvin Cohen, Christine Katlama, Beatriz Grinsztejn, Artur Timerman, Rogério de Jesus Pedro, Tony Vangeneugden, Diego Miralles, Sandra De Meyer, Wim Parys, Éric Lefebvre	2007	93
19	Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers Antiviral Therapy ·Monika Schöller‐Gyüre, Thomas N. Kakuda, Vanitha Sekar, Brian Woodfall, Goedele De Smedt, Éric Lefebvre, Monika Peeters, Richard M. W. Hoetelmans	2007	88
20	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis Clinical Gastroenterology and Hepatology ·Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Éric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, M. Hassan Murad, Mazen Noureddin	2018	86

About Éric Lefebvre

Éric Lefebvre is a scholar working on Virology, Hepatology, Infectious Diseases, Nuclear and High Energy Physics and Emergency Medicine, having authored 137 papers that have together received 6.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (37 papers), HIV Research and Treatment (34 papers), Laser-Plasma Interactions and Diagnostics (18 papers), Liver Disease Diagnosis and Treatment (16 papers), HIV/AIDS Research and Interventions (14 papers), Pharmacological Effects and Toxicity Studies (11 papers), Hepatitis C virus research (11 papers) and Laser-induced spectroscopy and plasma (10 papers). The work is most often cited by research in Virology (1.9k citations), Infectious Diseases (2.3k citations), Hepatology (912 citations), Nuclear and High Energy Physics (1.3k citations) and Emergency Medicine (687 citations). Éric Lefebvre has collaborated with scholars based in France, United States and Canada. Frequent co-authors include Tony Vangeneugden, V. Malka, Martine De Pauw, Sabrina Spinosa‐Guzman, Richard M. W. Hoetelmans, Vanitha Sekar, Sandra De Meyer, F. Burgy, S. I. Kiselev and D. Umstadter. Their work appears in journals such as Journal of Hepatology, AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes, Physical Review Letters and Physics of Plasmas.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact